March 25, 2011 (Pomona, California) — The use of fibrates in the US has increased steadily over the past 10 years and remained consistent in Canada, with the market share dominated by brand-name ...

We identified 1,116,805 statin and/or fibrate initiators who met eligibility criteria from January 1, 1998, through December 31, 2007. Of these, 86.6% were statin initiators, 12.9% were fibrate ...

Although recent evidence suggests that the clinical benefit may be uncertain for fibrates, a class of drugs used for the treatment of high lipid levels, use of these drugs is common in the US and ...

Fenofibric Acid (Fibrate (200 mg)) is used to reduce the cholesterol in patients with obesity problem. It is a HMG-CoA reductase inhibitor (statin). It slows the production of cholesterol in the body.

Use of combination of statin with niacin or fenofibrate for the treatment of high cholesterol levels is no longer approved by the FDA. The FDA is withdrawing approvals on the use of combination of ...

Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Fibrate Drugs Market by Drug Type, by Product Type, by Distribution Channel, and By Region" report has been added to ResearchAndMarkets.com's ...

Active ingredient: Fenofibric acid (as choline fenofibrate) 45 mg, 135 mg; delayed-release caps. Indications: Adjunct to diet: In combination with a statin, to reduce triglycerides (TG) and increase ...

APAC sees fibrates growth amidst urbanisation and healthcare spending. The fibrate drugs market is projected to reach a value of $1.8 b by 2034, with a compound annual growth rate of 2.12%, driven by ...

Fibrate use was associated with new onset CKD, but a lower risk for kidney failure. Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising ...

In a real-world Japanese study, recent fibrate use was associated with decreased odds of MACE among patients with CKD. Recent fibrate use is associated with reduced risks for major adverse ...